Clobazam Effective for Refractory Epilepsy in Children Younger Than 2
Clobazam is currently FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome in children 2 years and older.
Clobazam is currently FDA-approved for the treatment of seizures associated with Lennox-Gastaut syndrome in children 2 years and older.
The diagnostic tool may be especially useful in cases of nonlesional mesial temporal lobe epilepsy.
Patients with refractory epilepsy who fail to benefit from 2 or more AEDs should be referred to alternative therapies.
Patients who died from suspected SUDEP had extensive damage to areas of the mid-brain and brainstem that control autonomic function.
Researchers compared outcomes between patients treated with continuous infusion or repeated doses of nonbenzodiazepine anti-seizure medication.
The study was a post-hoc analysis of responders who were on or off concomitant clobazam.
Patients undergoing treatment for ischemic stroke are at greater risk for seizure development.
Treatment with positive airway pressure may help retain or improve seizure control in patients with epilepsy and obstructive sleep apnea.
Treatment algorithms are needed for patients with epilepsy who present with evidence of bone loss.
Researchers examined whether there are clinical features or treatments associated with neuropsychiatric outcomes in BECTS.